Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Exactech second quarter revenue increases 7% to $55.2 million

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $55.2 million for the second quarter of 2012, a 7% increase over $51.7 million in the second quarter of 2011.

31 Jul 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Pfizer Inc. announced today top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

31 Jul 2012

Childhood deprivation linked to rheumatoid arthritis in adults

Adults with rheumatoid arthritis are more likely to have grown up in a low socioeconomic environment during childhood than those without RA, a large US case–control study shows.

30 Jul 2012

Screening checks in adolescents with hypertension diverge from guidelines

Guideline-recommended diagnostic tests for hypertension complications, such as echocardiograms and renal ultrasonography, are being poorly used in adolescents, a study suggests.

30 Jul 2012

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, announces that the clinical portion of a human study of a solution version of TNX-102 2.4 mg sublingual tablets has completed.

30 Jul 2012

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech, a member of the Roche Group, today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

28 Jul 2012

Rituximab also benefits patients with kidney disorder

A drug commonly used to treat immune disorders such as lymphoma and arthritis also benefits patients with an immune disorder of the kidneys that can lead to kidney failure, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN).

28 Jul 2012

EC approves Vertex's KALYDECO for treatment of cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today that the European Commission has approved KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jul 2012

Anakinra can dramatically limit amount of brain damage in stroke patients

Scientists led by the President of The University of Manchester have demonstrated a drug which can dramatically limit the amount of brain damage in stroke patients.

From The University of Manchester 27 Jul 2012

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

The state can cut health care costs and reduce the number of medical-related lawsuits by requiring earlier notification of injuries as well as pretrial mediation, according to a recommendation Gov. John Kitzhaber issued Wednesday. The product of closed-door talks between representatives of interest groups including the Oregon Medical Association and the Oregon Trial Lawyers Association, Kitzhaber's recommendation now goes to a work group including lawmakers, a trial lawyer and doctor that begins public meetings next week.

27 Jul 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

Protalex, Inc., a clinical stage biopharmaceutical company that is developing a class of drugs designed to treat a wide array of autoimmune and inflammatory diseases today announced preliminary findings from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study.

26 Jul 2012

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A. Inc. today announced the filing of a supplemental new drug application (sNDA) with the US Food and Drug Administration (FDA) seeking approval for a new indication for AMITIZA (lubiprostone) for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain.

26 Jul 2012

Studies look at surgical site infections and hyperglycemia

Two recent studies in the July issues of the Journal of Bone and Joint Surgery (JBJS) looked at surgical site infections and hyperglycemia, the technical term for high blood glucose, or high blood sugar.

26 Jul 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2012 and provided an update on development programs.

25 Jul 2012

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.

25 Jul 2012

Questcor second quarter net sales increase to $112.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2012.

24 Jul 2012

Latest polypill trial yields largest improvements yet

The results of the first trial to administer the polypill on the basis of age alone has shown the largest reductions in blood pressure and cholesterol level of any polypill trial to date, researchers report.

24 Jul 2012

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Exactech second quarter revenue increases 7% to $55.2 million

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Australia's top medical researchers for 2012 announced

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Childhood deprivation linked to rheumatoid arthritis in adults

Screening checks in adolescents with hypertension diverge from guidelines

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Rituximab also benefits patients with kidney disorder

EC approves Vertex's KALYDECO for treatment of cystic fibrosis

Anakinra can dramatically limit amount of brain damage in stroke patients

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

Studies look at surgical site infections and hyperglycemia

Regeneron reports total revenues of $304 million for second quarter 2012

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

Questcor second quarter net sales increase to $112.5 million

Latest polypill trial yields largest improvements yet

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in